Abbott and Sanofi are partnering up to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes manage their condition.
The two companies plan to develop tools that combine the revolutionary FreeStyle Libre technology with Sanofi′s insulin dosing information for future smartpens, insulin titration apps, and cloud software.
The non-exclusive collaboration will initially enable data sharing, at the consent of the user, between Abbott′s FreeStyle Libre mobile app and cloud software and Sanofi′s connected insulin pens, apps and cloud software that are currently in development.
This data sharing will enable both people with diabetes and their doctors to make better-informed treatment decisions around medication, nutrition, and lifestyle.
“As the global leader in continuous glucose monitoring, we see a significant opportunity to impact the health of millions of people living with diabetes by developing new tools and connectivity with Sanofi, a leader in the insulin space,” said Jared Watkin, senior vice president, Diabetes Care, Abbott in a statement.
“Building a digital ecosystem around FreeStyle Libre simplifies the user experience by consolidating how people get their data – both through offering Abbott′s digital health tools and by working with other diabetes and technology leaders,” Watkins added.
Sanofi is currently working to provide connected pens, apps and cloud software that will be compatible with the FreeStyle Libre system and its compatible digital health tools.
